Go to content Go to the menu Go to the search

PartnersSorbonne UniversitésUPMCInsermCNRS
Quick access, personalized services
Centre d'Immunologie et des Maladies Infectieuses
UPMC UMRS CR7 - Inserm U1135 - CNRS ERL 8255

Immune-intervention and Biotherapy - François LEMOINE

Team members

Team research program

Our project is dedicated to the development of therapeutic vaccines in combination with other anti-cancer therapies with a special focus on head and neck cancers (HNSCCs). Research is carried out in experimental models and in patients, with the long-term goal to implement clinical trials, thanks to our tight links with clinical departments recruiting the patients
Our specific objectives are:

1) To develop anti-cancer vaccines derived from viral and non-viral vectors in vivo targeting dendritic cells.
We test vaccinal vectors functionalized with different sugar compounds as ligands of C-type lectins known to be by expressed by dendritic cell subsets, and we study their ability to elicit immune and anti-tumor responses in mice.

2) To improve the efficacy of curative vaccines in different animal tumor models.
We study different routes of vaccination and different adjuvants for eliciting systemic and mucosal immune responses. In this context, we use vaccinal vectors carrying the E7 oncoprotein from HPV-16, as a tumor antigen model, and test them in different tumor models of HNSCCs in mice.

3) To study tumor microenvironments both in mice and in patients.
In mice, we are studying  the interactions between immune and tumors cells before and after vaccines to better identify the mechanisms that give rise to immune responses and to tumor regression. In human, we are studying tumor environment of different cohorts of patients suffering from oral or oropharyngeal cancers that are or not HPV-induced.

4) To combine immunotherapy to targeted therapies.
Immunotherapy alone is not efficient enough to durably eradicate tumors. We are studying how combining therapeutic vaccines with strategies designed

  • to increase the sensibility of tumor cells to chemo/radiotherapy by blocking the DNA repair system;
  • to inhibit regulatory T lymphocytes and/or to stimulate effector T cells.

Technical expertise

  • Cellular immunology
  • Cell culture (human and mice)
  • Flow cytometry and cell sorting
  • Murine pre-clinical models

External funding (current)

At academic level:

  • DGOS / INSERM
  • Fondation ARC
  • Fondation des gueules Cassées
  • INCA / DGOS
  • INCA

From industry:

Novartis

Publications (PDF):

(2017 - 2016 - 2015 - 2014 - 2013)

23/10/17

Traductions :

Contact

cimi-paris @ upmc.fr

To see

Key words

Immunotherapy, Vaccine, Head and neck cancers, Biotherapy

Fields of application

Oncology, Immunomodulation